The purpose of the study is to determine whether the combination tablet provides better pain relief and is well tolerated compared with the single‑ingredient tablet and placebo. Over a period of about one week, participants take the assigned tablets at regular intervals and record their pain levels and any need for extra pain medication. Simple physical tests, such as reaching toward the floor, are performed at the start and at the end of the week to see if movement improves.

Participants in the study will receive either nucresiran or vutrisiran, which is a currently used treatment for this condition. These medications are administered as a subcutaneous injection, meaning the medicine is injected into the fatty tissue just under the skin. During the study, the effects of these drugs on nerve function and the levels of a protein called transthyretin in the blood will be observed over time.

The purpose of the study is to assess how well Efgartigimod works in improving symptoms of Ocular Myasthenia Gravis and to ensure it is safe for use. Participants in the study will receive either Efgartigimod or a placebo through subcutaneous injection, which means the injection is given under the skin. The study will monitor changes in the participants’ symptoms over a period of time, focusing on improvements in muscle strength around the eyes and overall well-being.

Throughout the study, participants will be closely observed for any side effects or changes in their condition. The trial aims to provide valuable information on the potential benefits of Efgartigimod for individuals with Ocular Myasthenia Gravis, contributing to the development of effective treatments for this condition. The study is designed to ensure the safety and well-being of all participants while gathering important data on the treatment’s impact.

Participants in the study will receive Ketamine through an intravenous infusion, which means it will be given directly into a vein. The study will last for a period of up to six weeks. During this time, researchers will monitor the participants to see how Ketamine affects their ability to stay abstinent from opioids, as well as any changes in their cravings and mood. The study also aims to identify certain biological markers, known as biomarkers, that might predict when someone is at risk of relapsing.

By understanding how Ketamine works in the context of opioid addiction treatment, the study hopes to provide new insights into how to better support individuals with OUD. This could lead to improved treatment options that help people maintain their recovery and improve their overall well-being. The study is part of ongoing efforts to find effective ways to combat opioid addiction and support those affected by it.

The purpose of the study is to determine if either duloxetine or furosemide can better control these types of pain over a period of three months. Participants will be randomly assigned to receive one of these medications or a placebo. The study will last for up to six months, during which participants will take the medication orally. The trial aims to assess changes in pain levels and overall quality of life using specific questionnaires designed to measure these aspects.

Throughout the study, participants will be monitored for any changes in their symptoms and overall health. The trial will also evaluate the safety of the medications by tracking any side effects or adverse events. The ultimate goal is to find supportive treatments that can help patients manage the side effects of their cancer therapy, thereby improving their quality of life during treatment.

Participants in the study will receive either the new treatment, Lutetium-177-PSMA, or follow the standard care. The treatment involves an injection of a solution that contains a radioactive substance, which is designed to target and destroy cancer cells. The study will monitor the participants to see how their cancer responds to the treatment and whether it helps in delaying the progression of the disease. The study will also look at other factors such as the participants’ quality of life and any side effects they may experience.

The trial will last for several months, and participants will be closely monitored throughout the process. The researchers aim to gather valuable information that could lead to improved treatment options for patients with prostate cancer. This study is an important step in exploring new ways to manage and treat this type of cancer, potentially offering new hope for patients in the future.

The purpose of the study is to evaluate how safe and tolerable eplontersen is when used over an extended period. Participants in the study will receive eplontersen through injections under the skin. The study will monitor various health indicators, such as blood tests, kidney function, and liver enzymes, to ensure the treatment is safe. Participants will also be asked about any side effects they experience and will undergo regular physical examinations and heart tests.

Throughout the study, changes in the participants’ symptoms and quality of life will be assessed using specific questionnaires and scores. These assessments will help determine if the treatment is effective in managing the symptoms of hATTR-PN. The study will also compare these results to baseline measurements taken at the start of the study. Participants will continue to receive the treatment and be monitored for a period of time to gather comprehensive data on the long-term effects of eplontersen.

The purpose of the study is to evaluate how well efgartigimod PH20 SC works in improving the symptoms of IIM, as well as to assess its safety and how well it is tolerated by participants. Participants in the study will receive either the investigational treatment or a placebo, and their progress will be monitored over a period of time to see if there are any improvements in their condition. The study will also look at how the body processes the treatment and whether it causes any immune reactions.

Throughout the study, participants will undergo various assessments to measure changes in muscle strength and overall disease activity. These assessments will help determine the effectiveness of the treatment in providing clinical improvement for those with active IIM. The study aims to provide valuable information on whether efgartigimod PH20 SC can be a beneficial treatment option for individuals with this condition.

Participants in the study will receive either the Efgartigimod IV treatment or a placebo. The study is designed to be double-blinded, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure that the results are unbiased. The study will follow a structured plan over a period of time, during which participants will be monitored for changes in their symptoms and any side effects they may experience.

The trial aims to provide valuable information about the potential benefits of Efgartigimod IV for people with Generalized Myasthenia Gravis who are seronegative for acetylcholine receptor binding antibodies. By comparing the effects of the treatment to those of a placebo, researchers hope to better understand how this medication can help manage the condition and improve the quality of life for those affected. Participants will be closely observed throughout the study to ensure their safety and to gather comprehensive data on the treatment’s impact.

The purpose of this study is to evaluate how safe this combination treatment is and how it behaves in the body. Participants will receive the treatment and be monitored for any side effects or reactions. The study will also look at how the body processes the medications, including how much of the drug is present in the blood at different times. This will help researchers understand the treatment’s safety and how it might work in treating solid tumors.

Throughout the study, participants will receive regular check-ups and tests to monitor their health and the effects of the treatment. The study aims to gather important information that could lead to new treatment options for people with solid tumors. The trial is expected to continue until late 2025, providing valuable insights into the potential benefits and risks of this new treatment combination.

The treatment involves high-dose radiation therapy delivered in 6 sessions, specifically targeting the prostate. This is combined with androgen deprivation therapy (hormone treatment that reduces male hormone levels) using goserelin implants. The radiation treatment is guided by special scans that use a substance called PSMA (prostate-specific membrane antigen) to create detailed images of the prostate.

The study will use artificial intelligence to analyze various medical images and information to help determine the best treatment approach. This includes looking at special prostate scans called magnetic resonance imaging (MRI) along with other tests. The treatment period will last several months, during which patients will receive both radiation therapy and hormone treatment, and their progress will be monitored for several years afterward.

The purpose of the study is to assess how effective and safe ALN-TTRSC02 is for patients with hATTR Amyloidosis. Participants in the study will receive the treatment as a solution for injection. The study will also compare the effects of ALN-TTRSC02 with another treatment called Onpattro, which is given as a solution for infusion. Some participants may receive a placebo instead of the active treatment. The study will monitor changes in nerve function and quality of life over time.

Throughout the study, participants will undergo regular assessments to track their progress and any changes in their condition. The study aims to provide valuable information on how ALN-TTRSC02 can help manage the symptoms of hATTR Amyloidosis and improve the lives of those affected by this condition.

Participants in the study will receive the treatment and be monitored for any side effects or changes in their health. The study will also look at how the treatment affects the use of other medications, such as glucocorticoids, which are often used to manage symptoms of the disease. The goal is to see if the treatment can help reduce the need for these medications over time.

Throughout the study, participants will have regular check-ups to monitor their health and the effectiveness of the treatment. This includes looking at various health indicators and assessing the overall improvement in their condition. The study will provide valuable information on the potential benefits and risks of using efgartigimod for treating idiopathic inflammatory myopathy.

The purpose of the study is to determine if early administration of ORENCIA can improve the clinical recovery of patients with COVID-19 over a period of 60 days. Participants in the study will receive either the medication or a placebo shortly after being hospitalized. The trial will monitor their recovery process, focusing on how quickly they recover and their overall health status during the study period.

The study will track several outcomes, including the time it takes for patients to recover, their survival rate, and any need for additional medical support like mechanical ventilation. Safety will also be closely monitored by observing any serious side effects or adverse events that may occur during the trial. The goal is to gather information that could help improve treatment strategies for patients with COVID-19 in the future.

Participants in the study will be randomly assigned to receive either elacestrant or one of the standard endocrine therapies, which include medications like tamoxifen, anastrozole, exemestane, and letrozole. Some patients may also receive additional treatments such as leuprorelin, goserelin, or triptorelin, which are used to lower hormone levels in the body. The study will last for a period of up to 104 weeks, during which the effects of the treatments will be monitored. The study aims to determine which treatment is more effective in preventing the cancer from spreading or causing death.

Throughout the study, participants will have regular check-ups and tests to monitor their health and the progress of the treatment. These tests may include imaging scans like MRI or CT scans, which use magnetic fields or X-rays to create detailed pictures of the inside of the body. The study will also collect information on the safety of the treatments and how they affect the quality of life of the participants. The results of this study could help improve treatment options for patients with this type of breast cancer in the future.

The purpose of the study is to see if giving chemotherapy before surgery can improve the chances of the cancer not coming back after surgery. Patients will be randomly assigned to receive either chemotherapy followed by surgery or surgery alone. The study will last for several years, and patients will be monitored for their health and any signs of cancer returning. The main focus is on how long patients remain free of cancer after treatment, which is called disease-free survival. Other aspects being studied include overall survival, the response of the cancer to the chemotherapy, and any side effects from the treatment.

Participants in the study will undergo various tests and procedures, including imaging tests like MRI and CT scans, to assess the size and spread of the cancer. These tests help doctors determine if the cancer can be surgically removed. The study aims to gather information that could help improve treatment strategies for patients with high-risk retroperitoneal sarcoma, potentially leading to better outcomes and quality of life.